Prevention of recurrent respiratory papillomatosis: Role of HPV vaccination

International Journal of Pediatric Otorhinolaryngology

Volumn 70, Issue 10, 2006, Pages 1799-1803

  Freed, Gary L ^a   Derkay, Craig S ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Cervarix ; Cervical cancer; Cervical intraepithelial neoplasia; Gardasil ; Genital warts; Human papilloma virus; Recurrent respiratory papillomatosis; Vaccine

Indexed keywords

ALUMINUM HYDROXYPHOSPHATE SULFATE; IMMUNOLOGICAL ADJUVANT; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

ABSENCE OF SIDE EFFECTS; ARTICLE; CANCER PREVENTION; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOSTIMULATION; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; PAPILLOMATOSIS; PRIORITY JOURNAL; RECURRENT INFECTION; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; VACCINATION; VIRUS CARCINOGENESIS; VIRUS TRANSMISSION;

ADULT; CHILD; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 6; HUMANS; PAPILLOMA; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RECURRENCE; RESPIRATORY TRACT NEOPLASMS;

EID: 33747882888     PISSN: 01655876     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijporl.2006.06.006     Document Type: Article

References (21)

1. Centers for Disease Control and Prevention, Sexually Transmitted Diseases Treatment Guidelines 2002, vol. 51, no. RR-6, MMWR 2002.
2. Alberg A.J., and Samet J.M. Epidemiology of lung cancer. Chest 123 Suppl. 1 (2003) 21S-49S
3. Kiviat N.B., Koutsky L.A., and Paavonen J. Cervical neoplasia and other STD-related genital tract neoplasias. In: Holmes K., Sparling P., Mardh P., et al. (Eds). Sexually Transmitted Diseases. 3rd ed. (1999), McGraw-Hill, New York 811-831
4. Shah K.V., Unger R., Derkay C.S., and Steinberg B.M. Papillomavirus Rep. 16 6 (2005) 333-338
5. Silverberg M.J., Thorsen P., Lindeberg H., Grant L.A., and Shah K.V. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet. Gynecol. 101 4 (2003) 645-652
6. Bomholt A. Juvenile laryngeal papillomatosis. An epidemiological study from the Copenhagen region. Acta Otolaryngol. 105 3-4 (1988) 367-371
7. Derkay C.S. Task force on recurrent respiratory papillomas. A preliminary report. Arch. Otolaryngol. Head Neck Surg. 121 (1995) 1386-1391
8. Armstrong L., Derkay C.S., and Reeves W.C. Initial results from the National Registry for juvenile-onset recurrent respiratory papillomatosis. Arch. Otolaryngol. Head Neck Surg. 125 (1999) 743-748
9. Reeves W.R., Ruparellia S.S., Swanson K.L., Derkay C.S., Marcu A., and Unger E.R. National registry for juvenile-onset RRP. Arch. Otolaryngol. Head Neck Surg. 129 9 (2003) 976-982
10. Ruparrelia S., Unger E.R., Nissenbaum R., Derkay C.S., and Reeves W.R. Predictors of remission in juvenile onset of recurrent respiratory papillomatosis. Arch. Otolaryngol. Head Neck Surg. 129 12 (2003) 1275-1278
11. Derkay C.S., and Schraff S. Survey of ASPO membership regarding management of RRP distal spread and the use of adjuvant therapies. Arch. Otolaryngol. Head Neck Surg. 130 (2004) 1039-1042
12. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347 21 (2002) 1645-1651
13. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6 5 (2005) 271-278
14. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (2004) 1757-1765
15. K. Ault, Prophylactic use of quadrivalent HPV (types 6, 11, 16, 18) L1 virus like particle vaccine reduces cervical intraepithelial neoplasia 2/3 and adenocarcinoma in situ risk, in press.
16. C. Satler, Efficacy of a prophylactic quadrivalent HPV types 6, 11, 16, 18 L1 virus-like particle vaccine for prevention of cervical dysplasia and external genital lesions, in press.
17. F.E. Skjeldestad, Prophylactic quadrivalent HPV types 6, 11, 16, 18 L1 virus-like particle vaccine (Gardasil) reduces cervical intraepithelial neoplasia 2/3 risk, in press.
18. T. Nolan, S.L. Block, K.S. Reisinger, C.D. Marchant, S.A. Rusche, et al., Comparison of the immunogenicity and tolerability of a prophylactic quadrivalent HPV types 6, 11, 16, 18 L1 virus-like particle vaccine in male and female adolescents and young adult women, in press.
19. Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J., Alvarez F.B., Bautista O.M., Jansen K.U., and Barr E. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. 107 1 (2006) 18-27
20. Red Book online, Status of Licensure and Recommendations for New Vaccines, 2006, http://www.aapredbook.org/vaccstatus.shtml.
21. Lindman J.P., Lewis L.S., Accortt N., and Wiatrak B.J. Use of the pediatric quality of life inventory to assess the health-related quality of life in children with recurrent respiratory papillomatosis. Ann. Otol. Rhinol. Laryngol. 114 7 (2005) 499-503